AQR Capital Management
RXRX icon

AQR Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

AQR Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
422,087
+177,696
+73% +$592K ﹤0.01% 2775
2026
Q1 		$750K Buy
+244,391
New +$944K ﹤0.01% 2916
2025
Q4 		– Sell
-14,910
Closed -$72.8K – 3633
2025
Q3 		$72.8K Buy
14,910
+1,010
+7% +$5.3K ﹤0.01% 3397
2025
Q2 		$70.3K Sell
13,900
-154,291
-92% -$758K ﹤0.01% 3220
2025
Q1 		$890K Buy
+168,191
New +$1.23M ﹤0.01% 2099
2024
Q2 		– Sell
-14,985
Closed -$149K – 2667
2024
Q1 		$149K Buy
+14,985
New +$167K ﹤0.01% 2300

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management's RXRX Position: Q2 2026 in Review

AQR Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 73% in Q2 2026, buying an estimated $592K and bringing the position to 422,087 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

AQR Capital Management first reported a position in RXRX in Q1 2024 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • AQR Capital Management held 422,087 shares of Recursion Pharmaceuticals worth $1.55M as of Q2 2026.
  • AQR Capital Management bought 177,696 Recursion Pharmaceuticals shares in Q2 2026, an estimated $592K.
  • Recursion Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2775 holding.
  • AQR Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.